Lab members

Dr. Ruth Perets is Director of the Women’s Cancer Laboratory and an Attending Physician and oncologist in the Oncology Division at Rambam Health Care Campus.

Dr. Perets graduated from the Faculty of Medicine of the Hebrew University at Hadassah Hospital, Jerusalem, where she completed both her MD and PhD degrees. Her doctoral thesis focused on the molecular role of the androgen receptor in prostate cancer, under the supervision of Prof. Eli Pikarsky. She completed her medical oncology residency at Rambam in 2015.

During her residency she performed a post-doctoral fellowship at the Dana-Farber Cancer Institute in Boston, MA, under the supervision of Prof. Ronny Drapkin. There her studies focused on testing the hypothesis that the most common subtype of ovarian cancer, high grade serous carcinoma, originates from the fallopian tube in women with BRCA1/2 mutations and in the general female population.

Currently Dr. Perets focuses her clinical work on genitourinary malignancies (prostate, bladder, kidney and testicular cancers) and on gynecological malignancies (ovarian, cervical and endometrial cancers). Dr. Perets is the principal investigator of all Phase 1 clinical trials in Rambam’s Oncology Division, and personally treats all Phase 1 patients while on study.

A member of the Clinical Research Institute at Rambam, Dr. Perets's research group focuses on understanding the early pathogenesis of ovarian cancer and evaluating the implications of early pathogenesis on treatment and prevention of ovarian cancer. She is also interested in the role of the fallopian tube lineage marker PAX8 in ovarian cancer and in normal development of the fallopian tube.

She is the recipient of numerous grants to study ovarian cancer pathogenesis, including the Israel Science Foundation grant for physician researchers, Israel Cancer Association grant, The FP7-Marie Curie reintegration grant, the women’s health at Rambam grant and the ICRF grant for clinical investigators. She is the author of several highly cited scientific publications in the field of prostate and ovarian cancer, and performs peer review for oncology and pathology journals.